As Seattle Genetics INC (SGEN) Share Value Rose, Tekla Capital Management LLC Has Trimmed Position

October 13, 2018 - By Louis Casey

Seattle Genetics, Inc. (NASDAQ:SGEN) LogoInvestors sentiment decreased to 1.24 in Q2 2018. Its down 0.37, from 1.61 in 2018Q1. It is negative, as 23 investors sold SGEN shares while 68 reduced holdings. 41 funds opened positions while 72 raised stakes. 160.01 million shares or 0.31% more from 159.52 million shares in 2018Q1 were reported. State Board Of Administration Of Florida Retirement System, a Florida-based fund reported 148,059 shares. Wellington Gp Ltd Liability Partnership stated it has 0.15% in Seattle Genetics, Inc. (NASDAQ:SGEN). Blair William & Il has 287,531 shares for 0.13% of their portfolio. 412 are held by Glenmede Tru Na. South Dakota Invest Council holds 0.06% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN) for 42,200 shares. Badgley Phelps Bell holds 4,450 shares or 0.02% of its portfolio. Aqr Ltd Limited Liability Company reported 35,675 shares or 0% of all its holdings. Meeder Asset Mngmt Incorporated accumulated 11 shares or 0% of the stock. Ameriprise Finance stated it has 702,007 shares. Platinum Inv Mngmt Limited stated it has 40,500 shares. Geode Capital Lc reported 1.02 million shares or 0.02% of all its holdings. Deutsche Bankshares Ag stated it has 404,616 shares or 0.02% of all its holdings. The Netherlands-based Apg Asset Mgmt Nv has invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). Nordea Investment Mgmt, a Sweden-based fund reported 2,762 shares. Pnc Financial Svcs Gp has 0% invested in Seattle Genetics, Inc. (NASDAQ:SGEN).

Since April 30, 2018, it had 2 buys, and 15 selling transactions for $63.25 million activity. 18,832 shares were sold by SIEGALL CLAY B, worth $1.30 million. $24.57 million worth of stock was bought by BAKER BROS. ADVISORS LP on Friday, May 4. Cline Darren S sold $831,688 worth of stock or 12,054 shares. LIU JEAN I sold 4,123 shares worth $306,058. SIMPSON TODD E sold $402,856 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) on Monday, August 27.

Tekla Capital Management Llc decreased its stake in Seattle Genetics Inc. (SGEN) by 19.36% based on its latest 2018Q2 regulatory filing with the SEC. Tekla Capital Management Llc sold 67,082 shares as the company’s stock rose 13.24% with the market. The institutional investor held 279,417 shares of the health care company at the end of 2018Q2, valued at $18.55 million, down from 346,499 at the end of the previous reported quarter. Tekla Capital Management Llc who had been investing in Seattle Genetics Inc. for a number of months, seems to be less bullish one the $11.56 billion market cap company. The stock increased 2.67% or $1.89 during the last trading session, reaching $72.77. About 570,815 shares traded. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 44.99% since October 13, 2017 and is uptrending. It has outperformed by 29.37% the S&P500.

Tekla Capital Management Llc, which manages about $1.06 billion and $2.64B US Long portfolio, upped its stake in Biogen Inc. (NASDAQ:BIIB) by 25,252 shares to 403,955 shares, valued at $117.24 million in 2018Q2, according to the filing. It also increased its holding in Blueprint Medicines Corporation by 71,780 shares in the quarter, for a total of 146,001 shares, and has risen its stake in Aetna Inc. (NYSE:AET).

Analysts await Seattle Genetics, Inc. (NASDAQ:SGEN) to report earnings on October, 25. They expect $-0.27 earnings per share, down 42.11 % or $0.08 from last year’s $-0.19 per share. After $-0.18 actual earnings per share reported by Seattle Genetics, Inc. for the previous quarter, Wall Street now forecasts 50.00 % negative EPS growth.

More notable recent Seattle Genetics, Inc. (NASDAQ:SGEN) news were published by: Seekingalpha.com which released: “Key events next week – healthcare” on October 12, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on September 25, 2018, Businesswire.com published: “Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to Be Presented at ESMO 2018 Congress” on October 08, 2018. More interesting news about Seattle Genetics, Inc. (NASDAQ:SGEN) were released by: Nasdaq.com and their article: “Research Report Identifies Ultragenyx Pharmaceutical, Helmerich & Payne, Buckeye Partners, Covanta Holding …” published on October 03, 2018 as well as Seekingalpha.com‘s news article titled: “Seattle Genetics’ Adcetris successful in late-stage study in first-line PTCL” with publication date: October 01, 2018.

Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Coverage

Among 5 analysts covering Seattle Genetics (NASDAQ:SGEN), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Seattle Genetics had 5 analyst reports since April 27, 2018 according to SRatingsIntel. The rating was maintained by Barclays Capital on Wednesday, October 3 with “Overweight”. The stock has “Buy” rating by H.C. Wainwright on Friday, April 27. The rating was maintained by JP Morgan on Friday, July 27 with “Overweight”. SunTrust upgraded Seattle Genetics, Inc. (NASDAQ:SGEN) on Monday, June 11 to “Buy” rating.

Seattle Genetics, Inc. (NASDAQ:SGEN) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>